Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2017
At a glance
- Drugs Mirabegron (Primary)
- Indications Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera; Thrombocytopenia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 28 Dec 2016 Status changed from active, no longer recruiting to completed.
- 06 Dec 2016 Primary endpoint (Reduction in the burden of mutated alleles of 50% at 24 weeks) has not been met, according to results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.